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published RTOG study 0933). Assessment of health status and 
neurocognitive function after hyperfractionated radiotherapy 
of CSA in the SIOP PNET IV trial showed in part a better 
outcome as compared with conventional fractionation, 
especially in younger children. 
Conclusions: The impact of radiotherapy on the risk for late 
effects and its clinical pattern apparently strongly depends 
on the exposure of functionally relevant regions within the 
brain to irradiation. Neuroregeneration and the preservation 
of the corresponding anatomical regions may play an 
important role in the reduction of radiation induced decline 
of cognitive function. The impact of fractionation on the risk 
to develop a decline in neurocognitive function is 
controversial and requires further research.            
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Purpose: Reported experiences focusing on vulvo-vaginal 
brachytherapy during childhood are rare and most reported 
children have been treated at Gustave Roussy in France. Our 
technique of gynaecological brachytherapy has always 
been anatomy-adapted with use of the mould applicator. 
Here, we assessed the long-term toxicities of conservative 
treatments integrating brachytherapy in female survivors 
with localized vulvo-vaginal tumors. 
Patients and Methods: The data from 42 patients treated at 
Gustave Roussy between 1971 and 2004, were both 
retrospectively and prospectively analyzed. Strictly 
confidential surveys buildup based on the LENT SOMA 
questionnaires were mailed and 51% were filled up (minor: 
29%; adult: 71%). Complications were recorded throughout 
follow-up and graded according to the CTCAE version 4.0. 
Results: The median age at diagnosis was 1.7 years (range, 
0.6-16.6) and most patients (69%) had rhabdomyosarcomas. 
Treatments included brachytherapy for all patients, 
chemotherapy (88%), surgery (31%), and external-beam 
radiotherapy (5%). At a median follow-up of 15.5 years, 
41/42 patients were alive. There was 160 late effects 
identified in 32/42 (76%) patients: 72% G1-G2, and 28% G3-4 
(mean all grade late effect per patients: 4±4 [median: 2.5; 
range, 0-16] and mean G3-4 late effect per patients: 1±1.9 
[median: 0; range, 0-8]). The most commons late toxicities 
were gynecologic for all grade (75/160; 47%) and urinary for 
G3-4 (24/45; 53%). Fourteen patients (33%) required surgical 
treatment of late complications. The 15-year actuarial 
incidence rate of G3-4 late effects was 51%. The total 
number of all grade and G3-4 late effects was significantly 
increased in patients treated before 1990 (p=0.005 and 
p=0.008) and with higher cumulated dose (p=0.03 and 
p=0.02) and maximal dose delivered to ovaries (p=0.002 and 
p=0.04), and larger brachytherapy volume (p=0.03 and 
p=0.02). Quality of life was good or very good in 91% of 
patients that answered the surveys.  
Conclusion: The burden of late effects decreased with 
advances in treatment. A highly specialized multidisciplinary 
approach combining stringently controlled brachytherapy 
parameters, elective surgical indications, and efficient 
chemotherapy regimens should allow pursue improvements in 
terms of long-term sequelae. 
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Side effects after external radiotherapy in pediatric oncology 
are multifaceted and depend on the age of the patient at 
time of treatment, location, size of the target volume, and 
the OAR inside or in the neighborhood of the target. Not only 
high doses do have an effect on the growing structures but as 
well low doses can provoke severe long term side effects. 
Most of the side effects are not visible during the first 5 years 
after treatment but develop continuously over decades, and 
can influence quality of lifelong. Based on the experience in 
pediatric radiooncology and dose distribution at the growing 
structures, most of these side effects are predictable and 
some of them are avoidable using adequate techniques. 
According to the age of the patient different long term side 
effects are to be aspected. For example children in the of > 
than 9 years after mantel field irradiation have a much 
higher risk to develop breast carcinoma than younger 
children, meanwhile the growing deficit of the bones are 
much pronounced after RT in younger children than in older 
ones. Due to the combined treatment schedules most of the 
side effects are combined and the real dimension of RT–dose 
and irradiated volume cannot always be evaluated. Based on 
different patient cases the development of long term side 
effects will be discussed. 
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Purpose/Objective: Improved childhood cancer survival is 
accompanied by an increased incidence of tumor- and 
treatment-related adverse events later in life. 
Cerebrovascular accidents (CVAs) including ischemic and 
hemorrhagic stroke are amongst the most serious events. The 
purpose of this study was to determine the incidence and 
severity of symptomatic CVAs occurring 5 years or later after 
the primary cancer diagnosis in a cohort of long-term 
childhood cancer survivors, and to assess dose-effect 
relationships for cranial radiotherapy (CRT) and 
supradiaphragmatic radiotherapy (SDRT). 
Materials and Methods: The single-center study cohort 
consisted of 1362 ≥5-year survivors diagnosed between 1966 
and 1996; two survivors who had a CVA within 5 years after 
diagnosis were excluded from the cohort. CVAs were 
clinically confirmed, and defined and graded for severity 
using the Common Terminology Criteria for Adverse Events 
(CTCAEv.3.0). Physical radiation doses were available for 411 
(93.8%) of the 438 survivors treated with CRT and/or SDRT, 
and converted into the equivalent dose in 2-Gy fractions 
(EQD2). Cox proportional hazard models were used to 
estimate the hazard ratio (HR) and 95% confidence interval 
(95%CI) for sex, age at diagnosis, brain surgery, 
chemotherapy, CRT and SDRT. In a second model, the 
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relationship between the EQD2 for both treatment locations 
(CRT, SDRT) and the occurrence of a first CVA was assessed. 
Results: After a median time of 24.9 years from the primary 
diagnosis and at a median attained age of 31.2 years, 28 
survivors had a first CVA. Of them, 18 (64.3%) had ischemic 
events (Grade 3-4), and 10 (35.7%) had hemorrhagic events 
(Grade 2-5). One survivor was not treated with CRT nor with 
SDRT. Subsequently, two survivors had a second, and one a 
third CVA. The 35-year cumulative hazard in survivors treated 
with CRT only was 14.2% (95%CI, 3.5-24.9%), in survivors 
treated with SDRT only 6.8% (95%CI, 0-13.7%), and in 
survivors who received both CRT and SDRT 24.3% (95%CI, 6.7-
41.8%) (Figure). The Cox analyses showed that both 
treatment locations significantly increased the risk of CVA in 
a dose-dependent manner (HRCRT 1.02 Gy-1; 95%CI, 1.01-1.03, 
and HRSDRT 1.04 Gy-1; 95%CI, 1.02-1.05). 
 
 
Figure. Cumulative hazards and 95%CIs for the first CVA ≥5 
years after the primary cancer diagnosis in survivors treated 
with CRT only, SDRT only, both CRT and SDRT, and in 
survivors who had no CRT and no SDRT. 
Note: The SDRT only group consisted of 95 survivors; SDRT 
treatment could not be confirmed for 3 survivors, leaving 92 
survivors for analysis. 
Conclusions: Our results demonstrate that childhood cancer 
survivors treated with CRT and/or SDRT have an increased 
risk of CVAs as compared with survivors who had no CRT and 
no SDRT. Thirty-five years after treatment, almost 1 in 4 
childhood cancer survivors treated with both CRT and SDRT 
experience a symptomatic CVA. In addition, these radiation-
associated CVAs occur at a very young age. Therefore, 
continuing follow-up with a focus on tailored preventive 
strategies to reduce the risk of CVAs in this young population 
deserves special attention. 
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Purpose/Objective: Paediatric metastatic medulloblastoma 
requires intensive treatment for the best results. Since 2007 
the majority of UK centres used the Milan strategy (High dose 
Chemotherapy and twice daily Radiotherapy) to treat these 
patients. There were some reported cases of profound 
neurotoxicity and a review of plans and treatment method 
was done in order to check whether radiotherapy had 
contributed to the toxicity. 
Materials and Methods: Patients with Grade 3-4 
neurotoxicity, treated between 2008 and 2014, were 
identified and the toxicities classified into global and 
myelitis. Plan data (CT planning scans, Plans and Dosegrids) 
for the CranioSpinal (CNS) phase 1 and the Posterior Fossa 
Boost (PFB) phase 2 , was collected and imported into Eclipse 
(Varian). The dosimetry was reviewed for individual and 
summed phases. Where possible MR images showing myelitis 
were blended with the dose distribution on the CT scan. A 
questionnaire was circulated around all Centres to establish 
the RT technique and immobilisation used. 
Results: 10 cases (8 male, all under 12 years), from 6 Centres 
were reviewed. All the children had a poor response to 
induction chemotherapy and received thiotepa as part of 
their high dose chemotherapy regime. The CNS dose was 
39Gy in 30 Fr for 9 cases and 31.2 Gy in 1 Fr for 1. All 
received a PFB to a dose of 59.7 – 60 Gy. All Centres used a 
conformal Linac based technique with opposed Head fields 
matched to posterior Spine fields, and a shifting gap. 5 out of 
6 centres used a supine technique. 1 Centre used VMAT for 
the PFB, others a 3DCRT plan. 1 Centre checked plans using 
summed doses, others checked each phase separately. The 
myelitis occurred in the PFB volume and it was noted that for 
these patients the C1 summed dose was >62 Gy, although less 
than 63Gy (105%), see Fig 1.  
 
 
Conclusions: There was no evidence of radiation techniques 
contributing to neurotoxicity. However when the Milan 
protocol was adapted for the UK, there was no involvement 
of physics and certain details of the treatment were 
different, in particular that in Milan the PFB PTV would not 
include the spinal cord. This review also highlighted the 
importance of planning and summing both phases in order to 
assess the combined dose. It is recommended that special 
attention is paid to the cervical spinal cord dose with a strict 
dose constraint of 61Gy. Lessons learnt from this review 
highlight the importance of sharing experience both 
nationally and internationally especially for rare tumours. 
   
 
Debate: SBRT / oligometastatic disease: Oligomets then 
SABR is standard of care  
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Stereotactic Body Radiotherapy (SBRT) is today the accepted 
standard of care for early stage non-small cell lung cancer if 
